About Us
Today's PBMs focus on maximizing rebates to manage pharmacy costs. RxResultsSM uses an evidence-based approach that focuses on lowest net cost. This significant difference is at the core of why employers, health plans and their members are paying more than they need to for prescription drugs.
The RxResults Approach
RxResults is backed by the University of Arkansas for Medical Sciences (UAMS) College of Pharmacy's evidence-based program – EBRx. EBRx evaluates drugs and drug categories focusing solely on clinical equivalence and efficacy. EBRx's evaluations are based on current medical literature and best-practices including:
- Oregon Health and Science University's Centers for Evidence-Based Policy,
- Cochrane Central Register of Controlled Trials,
- Cochrane Database of Systematic Reviews,
- DARE and
- MEDLINE.
The results of these evaluations are compared to the utilization data from your current drug plan to identify opportunities for additional savings.
Our Guiding Principle
The RxResults' model will take rebate information into consideration, but caution must be exercised not to maximize rebates. Significant opportunities exist in top drug categories to drive lower-cost generics or utilize clinical edits on selected brand-name drugs to lower your net plan costs. But, both scenarios often also reduce rebate revenue. PBMs often benefit most from rebates so they generally don't encourage this management model.
RxResults believes that doing what's best for patients and payers is paramount. That's why we make management recommendations that are evidence- based, designed to deliver optimal patient care, and reduce your overall drug spend.
About UAMS College of Pharmacy read more -->
We deliver the lowest net cost through evidence-based practices.